New combo therapy aims to beat back tough lymphomas
NCT ID NCT07077512
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a combination of two drugs—a CAR-T cell therapy (relmacabtagene autoleucel) and a PD-1 inhibitor (sintilimab)—in 30 adults with relapsed or refractory B-cell lymphoma. The goal is to see if the combo can shrink tumors and improve survival. Participants receive the CAR-T infusion first, then start the PD-1 inhibitor about a month later, continuing for up to a year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CAR-T cell therapy (relmacabtagene autoleucel) plus a PD-1 inhibitor (sintilimab)
What this could lead to
If successful, this combination could offer a new treatment option for patients with hard-to-treat B-cell lymphomas that have not responded to standard therapies.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. Side effects from CAR-T therapy and PD-1 inhibitors can be serious, including immune reactions and organ inflammation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA (FL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fifth Affiliated Hospital of Guangzhou Medical University
NOT_YET_RECRUITINGGuangzhou, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Guangzhou overseas Chinese hospital
NOT_YET_RECRUITINGGuangzhou, 510632, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sun Yat-sen Universitiy Cancer Center
RECRUITINGGuangzhou, 51000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••